PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH)...
Hence then, the article about ribox therapeutics announces first patient dosed in phase i iia clinical trial of rxrg001 the first circular rna therapy for the treatment of radiation induced xerostomia and hyposalivation was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation )
Also on site :
- From collapse fears to resilience: How Russia reshaped its economy by the end of 2025
- Russian MOD shows map of Ukrainian drone attack on Putin’s residence
- Advantech Unveils Next-Generation Edge AI Compute Solutions Powered by Qualcomm Dragonwing IQ-X Series